Skip to content

MedVector

2 viewers · 30d

Total raised

$1.0M

1 filing since 2025 · latest Options filed

Cumulative raised
LAST ROUND
Options · $1.0M
ROUNDS
1
INVESTORS
1
FOUNDED
N/A
HQ
El Segundo, CA
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

MedVector operates a telehealth platform that extends clinical trials beyond trial sites by turning a treating physician's office into an extension of the trial site. Its system lets a principal investigator at the trial site run trial sessions remotely with a patient's own physician, who monitors the patient's response under the investigator's instruction, so the physician never has to become a clinical trial investigator. The platform handles patient identification, referral matching, and compensating physicians for the added workload while preserving the patient-physician relationship. The company is based in El Segundo, California.

What sets it apart

Rather than recruiting patients away from their doctors, MedVector keeps the treating physician in the loop and makes their office a remote extension of the trial site, so patients hear the trial recommendation from a doctor they already trust and physicians can refer without taking on investigator responsibilities.

Funding history

1 round
Options+1Oct 7, 2025
Form D/A
+$1.0M$1.0M total

Latest SEC filings

via EDGAR · CIK 0001820902
Form D/A · Oct 7, 2025View on EDGAR

Products

1 tracked

MedVector telehealth clinical trial platform

Clinical trial technology

A telehealth and healthcare-provider engagement platform that connects treating physicians to clinical trial sites, allowing a principal investigator to conduct trial sessions with a patient at their own physician's office and instruct that physician's staff on monitoring the patient's response.

  • Telehealth link between the trial site principal investigator and the treating physician's office
  • Patient identification and referral matching
  • Physicians refer without becoming clinical trial investigators
  • Preserves the patient-physician relationship during trial participation